Multiple Myeloma: Multiplying Therapies

Novel therapies for multiple myeloma

Perspectives Promising therapies in multiple myeloma

Progress in medical research has enhanced our understanding of tumor biology, delineated genetic and molecular mechanisms of tumor growth and survival, and defined the impact of the microenvironment in cancer pathogenesis. As a consequence of these advances, cancers deemed rapidly fatal only a few decades ago can now be treated effectively, with prolonged survival in an increasing proportion of...

Antibody-Based Therapies in Multiple Myeloma

The unmet need for improved multiple myeloma (MM) therapy has stimulated clinical development of monoclonal antibodies (mAbs) targeting either MM cells or cells of the bone marrow (BM) microenvironment. In contrast to small-molecule inhibitors, therapeutic mAbs present the potential to specifically target tumor cells and directly induce an immune response to lyse tumor cells. Unique immune-effe...

Molecularly Targeted Therapies in Multiple Myeloma

Multiple myeloma (MM) is a hematological malignancy that remains incurable because most patients will eventually relapse or become refractory to the treatments. Although the treatments have improved, the major problem in MM is the resistance to therapy. Novel agents are currently in development for the treatment of relapsed/refractory MM, including immunomodulatory drugs, proteasome inhibitors,...

Multiple Myeloma Update

This literature review presents the most recent developments in the management of multiple myeloma, which is characterized by the presence of abnormal plasma cells (myeloma cells) that accumulate into the bone marrow. Aspects related to pathophysiology, clinical manifestations, laboratory, study and treatment are described. These pieces of information  are necessary to accomplish a better ...